SCHEMBL10131475

SCHEMBL10131475

COc1ccc(N2CCC(=O)CC2)nc1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
SUV39H2 Q9H5I1 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ROCK2 O75116 2/20 0.35
OGA O60502 1/20 0.35
GAA P10253 1/20 0.35
HCRTR1 O43613 2/20 0.34
HCRTR2 O43614 2/20 0.34
ALDH1A1 P00352 2/20 0.34
USP2 O75604 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
UCHL3 P15374 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10131403 0.81 TNF (0.40) NPC1RAB9AKMT2AGAALMNA
SCHEMBL10112520 0.80 PIM1 (0.34) KMT2AKDM4EALDH1A1CYP1A2LMNA
SCHEMBL20590758 0.78 KDM4E (0.42) NPC1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL10131219 0.78 HRH3 (0.51) NPC1RAB9AKMT2AKDM4EGAA
SCHEMBL10112743 0.77 KHK (0.43) NPC1RAB9AGAAALDH1A1USP2
SCHEMBL17893618 0.76 UCHL3 (0.39) NPC1RAB9AKMT2ASUV39H2KDM4E
SCHEMBL17310233 0.73 MAP4K4 (0.54) SUV39H2ALDH1A1LMNAMAPT
SCHEMBL10200659 0.71 PIM1 (0.45) SUV39H2ROCK2GAA
SCHEMBL7491417 0.71 HRH3 (0.45) NPC1RAB9AKMT2AKDM4EGAA
SCHEMBL7492849 0.71 SUV39H2 (0.40) SUV39H2ALDH1A1USP2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 NPC1 408/4885RAB9A 2120/4885KMT2A 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.